PMID- 30197797
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220321
IS  - 2095-3941 (Print)
IS  - 2095-3941 (Linking)
VI  - 15
IP  - 3
DP  - 2018 Aug
TI  - Yttrium-90 transarterial radioembolization versus conventional transarterial 
      chemoembolization for patients with hepatocellular carcinoma: a systematic review 
      and meta-analysis.
PG  - 299-310
LID - 10.20892/j.issn.2095-3941.2017.0177 [doi]
AB  - OBJECTIVE: To compare the effects and safety of conventional transarterial 
      chemoembolization (cTACE) and yttrium-90 transarterial radioembolization [TARE 
      (90Y)] for hepatocellular carcinoma (HCC). METHODS: Nine high-quality 
      observational studies, one low bias-risk randomized controlled trial (RCT), and 
      one moderate bias-risk RCT included 1,652 patients [cTACE, 1,124; TARE (90Y), 
      528], from whom data were extracted for this systematic review and meta-analysis. 
      RESULTS: The extracted study outcomes included 1-year and 2-year overall survival 
      (OS) rates, objective responses (ORs), and serious adverse events (AEs). 1-year 
      OS rates: OR = 0.939, 95 % CI: 0.705-1.251, P = 0.66. 2-year OS rates: overall 
      pooled OR = 0.641, 95% CI: 0.382-1.075, P = 0.092; observational study subgroup 
      OR = 0.575, 95% CI: 0.336-0.984, P = 0.043; RCT subgroup OR* = 0.641, 95% CI: 
      0.382-1.075, P = 0.346. OR: overall pooled OR = 0.781, 95% CI: 0.454-1.343, P = 
      0.371; mRECIST subgroup OR = 0.584, 95 % CI: 0.349-0.976, P = 0.040; WHO subgroup 
      OR = 1.065; 95% CI: 0.500-2.268, P = 0.870. Serious AEs: overall pooled RR = 
      1.477, 95% CI: 0.864-2.526, P = 0.154; RCT subgroup RR = 0.680, 95% CI: 
      0.325-1.423, P = 0.306; observational study subgroup RR = 1.925; 95 % CI: 
      0.978-3.788, P = 0.058. CONCLUSIONS: TARE (90Y) increased 2-year OS rates in the 
      observational subgroup and resulted in better OR rates, according to mRECIST 
      criteria, in comparison with cTACE. Furthermore, a lower risk of AEs was observed 
      for TARE (90Y) than for cTACE.
FAU - Yang, Yi
AU  - Yang Y
AD  - School of Medical Imaging, Tianjin Medical University, Tianjin 300203, China.
AD  - Department of Interventional Therapy, Tianjin Medical University Cancer Institute 
      and Hospital, National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin 300060, China.
FAU - Si, Tongguo
AU  - Si T
AD  - Department of Interventional Therapy, Tianjin Medical University Cancer Institute 
      and Hospital, National Clinical Research Center for Cancer; Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for 
      Cancer, Tianjin 300060, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Cancer Biol Med
JT  - Cancer biology & medicine
JID - 101588850
PMC - PMC6121048
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - conventional transarterial chemoembolization
OT  - transarterial radioembolization
OT  - yttrium-90
EDAT- 2018/09/11 06:00
MHDA- 2018/09/11 06:01
PMCR- 2018/08/01
CRDT- 2018/09/11 06:00
PHST- 2018/09/11 06:00 [entrez]
PHST- 2018/09/11 06:00 [pubmed]
PHST- 2018/09/11 06:01 [medline]
PHST- 2018/08/01 00:00 [pmc-release]
AID - cbm-15-3-299 [pii]
AID - 10.20892/j.issn.2095-3941.2017.0177 [doi]
PST - ppublish
SO  - Cancer Biol Med. 2018 Aug;15(3):299-310. doi: 
      10.20892/j.issn.2095-3941.2017.0177.